Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

ABSTRACT: “Direct to Drug” screening as a precision medicine tool in multiple myeloma

PROVIDER: PRJNA627346 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11586900_1.fastq.gz	Fastqsanger.gz
	SRR11586900_2.fastq.gz	Fastqsanger.gz
	SRR11586901_1.fastq.gz	Fastqsanger.gz
	SRR11586901_2.fastq.gz	Fastqsanger.gz
	SRR11586902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 76

Similar Datasets

“Direct to Drug” screening as a precision medicine tool in multiple myeloma

Project description:Seventy-six FDA approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin’s lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation and transcriptional profiles. We investigated the predictive value of anti-apoptotic BCL2 family member transcriptomic ratios as biomarkers of venetoclax sensitivity. RNA-seq analysis was available in 38 primary patient samples, from which we identified the 9 most (median AUC 0.09409) and least (median AUC 0.7195) sensitive samples to venetoclax.

2020-05-22 | GSE148715 | GEO

"Direct to Drug" screening as a precision medicine tool in multiple myeloma.

Project description:Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and transcriptional profiles. In primary MM samples, proteasome inhibitors, dinaciclib, selinexor, venetoclax, auranofin, and histone deacetylating agents had the broadest cytotoxicity. Of interest, newly diagnosed patient samples were globally less sensitive especially to bromodomain inhibitors, inhibitors of receptor tyrosine kinases or non-receptor kinases, and DNA synthesis inhibitors. Clustering demonstrated six broad groupings of drug sensitivity linked with genomic biomarkers and clinical outcomes. For example, our findings mimic clinical observations of increased venetoclax responsiveness in t(11;14) patients but also identify an increased sensitivity profile in untreated patients, standard genetic risk, low plasma cell S-Phase, and in the absence of Gain(1q) and t(4;14). In contrast, increased ex vivo responsiveness to selinexor was associated with biomarkers of poor prognosis and later relapse patients. This "direct to drug" screening resource, paired with functional genomics, has the potential to successfully direct appropriate individualized therapeutic approaches in MM and to enrich clinical trials for likely responders.

| S-EPMC7214452 | biostudies-literature

Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

Project description:Patient-Derived Xenografts of Upper Tract Urothelial Cell Carcinoma: a tool for precision medicine

| PRJNA554654 | ENA

Precision Medicine for Inherited Retinal Degenerations

Project description:Precision Medicine for Inherited Retinal Degenerations

| PRJNA736120 | ENA

Precision Medicine for Inherited Retinal Degenerations

Project description:Precision Medicine for Inherited Retinal Degenerations

| PRJNA736121 | ENA

The Brazilian Initiative on Precision Medicine (BIPMed)

Project description:The development of precision medicine strategies requires prior knowledge of the genetic background of the target population. However, despite the availability of data from admixed Americans within large reference population databases, we cannot use these data as a surrogate for that of the Brazilian population. This lack of transferability is mainly due to differences between ancestry proportions of Brazilian and other admixed American populations. To address the issue, a coalition of research centres created the Brazilian Initiative on Precision Medicine (BIPMed), an initiative of five Research Innovation and Dissemination Centers (RIDCs) supported by FAPESP.

2020-08-22 | GSE156652 | GEO

Precision medicine for ABCA4 disease: modifier alleles

Project description:Precision medicine for ABCA4 disease: modifier alleles

| PRJNA717338 | ENA

Precision medicine for ABCA4 disease: modifier alleles

Project description:Precision medicine for ABCA4 disease: modifier alleles

| PRJNA717339 | ENA

The Brazilian Initiative on Precision Medicine (BIPMed)

Project description:The Brazilian Initiative on Precision Medicine (BIPMed)

| PRJNA658602 | ENA

Two circulating biomarkers are associated with the serological status of Rheumatoid Arthritis patients: a tool for precision medicine strategies

Project description:In the present work, we aimed to carry out a pipeline based on quantitative proteomics tools to discover, verify and validate circulating proteins that are associated with the presence in serum of RF and ACPA and may therefore have potential for the stratification of RA patients and the application of precision medicine strategies based on these molecular signatures.

2023-03-11 | PXD037386 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data